Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 13Neoplasms 9Stomach Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Oropharyngeal Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2Solid Tumors 2Sarcoma 2Salivary Gland Neoplasms 2

Interventions

pembrolizumab 1Saline Solution 1Pemetrexed 1Nivolumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Non-Squamous Non-Small Cell Lung Cancer × Docetaxel × 90 days × Clear all
NCT07246863 2026-04-21

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

CatalYm GmbH

Phase 2 Recruiting
131 enrolled
Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡